en · de · es · pt
methods-notes.peptides5388.com › Data › Chemical Identity And Research Background — 2026 Update

Chemical Identity And Research Background — 2026 Update

By Editorial Desk · published 2026-03-13 · last reviewed 2026-05-04 · Data

This is a working overview of Melanocortin receptor, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2026-05-04 and is reviewed periodically as new material appears.

Chemical Identity and Research Background

Semax is a synthetic heptapeptide whose sequence is Met-Glu-His-Phe-Pro-Gly-Pro. The first four residues correspond to the ACTH(4-10) fragment, while the terminal Pro-Gly-Pro extension was added to improve metabolic stability. Its molecular formula is C37H51N9O10S and its monoisotopic mass is approximately 813.9 Da. The compound is classified as a peptide research chemical and as a registered pharmaceutical product in Russia, but it does not hold marketing approval in the European Union or the United States. Naming conventions vary across supplier catalogs.

Development of the compound took place in the Soviet Union during the 1980s, largely through peptide research groups affiliated with the Shemyakin-Ovchinnikov Institute and Moscow State University. Investigators screened fragments of adrenocorticotropic hormone for activity on the central nervous system while attempting to separate cognitive effects from hormonal ones. The shortened sequence was selected because it retained behavioral activity in animal models without stimulating corticosteroid release. Early publications described the molecule as an ACTH(4-10) analog.

Background and Development History

The parent fragment ACTH(4-10) carries the sequence Met-Glu-His-Phe-Arg-Trp-Gly. Semax replaces the arginine and tryptophan positions with a proline-glycine-proline tail, giving Met-Glu-His-Phe-Pro-Gly-Pro. That change removes residues associated with adrenal stimulation, so the peptide does not drive cortisol release the way full ACTH does. This distinction shapes how the compound is grouped in the literature, where it sits with neuropeptides and peptide neuromodulators rather than with corticosteroids.

Regulatory status varies sharply by country. Semax is registered for medical use in Russia, where it appears in formularies as a nasal solution, and it also holds registration in a small number of neighbouring states. It has no approval from the United States Food and Drug Administration or the European Medicines Agency, and it is not a scheduled controlled substance in most jurisdictions. Elsewhere it circulates mainly as laboratory material, so purity documentation comes from suppliers rather than from a national pharmacopoeia.

Semax is a synthetic peptide created in the Soviet Union during the early 1980s by researchers working in Moscow. It was built from the short adrenocorticotropic hormone fragment known as ACTH(4-10), and the chain was then extended with three additional amino acids. The resulting molecule was named semax and entered clinical use in Russia in 1994. It is generally described as a nootropic and neuroprotective agent rather than as a hormone analogue.

Semax at a glance

PropertyValueNotes
Molecular formulaC37H51N9O10SSeven-residue peptide
Molecular mass813.9 DaMonoisotopic value
AppearanceWhite to off-white powderLyophilized form
SolubilityFreely soluble in waterAlso soluble in saline and polar solvents
Storage (dry)-20 °C or lowerDesiccated, protected from light

研发背景与监管地位

各国监管态度分化明显。俄罗斯按处方药管理,部分东欧国家留有使用记录;欧盟与美国未批准其作为药物上市,市面流通品通常标注为研究用化学品。身份差异意味着标示含量、纯度与无菌性缺少统一核查。体育领域还牵涉反兴奋剂名录,跨境携带则受目的地药品法规约束。

Semax 是人工设计的七肽,序列为 Met-Glu-His-Phe-Pro-Gly-Pro,骨架取自促肾上腺皮质激素片段 ACTH(4-10)。它于二十世纪八十年代在苏联的分子遗传学研究机构内合成。设计目标是保留该片段与注意力和记忆相关的活性,同时剔除促皮质激素释放等内分泌作用。此后俄罗斯将其登记为药品并进入临床使用。

当时的短肽研究普遍关注能否穿越血脑屏障、在低剂量下产生中枢效应,Semax 属于这一路线。鼻内给药是其主要使用方式,俄语文献报道的适应症涵盖缺血性卒中、短暂性脑缺血发作、认知功能减退以及视神经病变。这些研究大多发表在当地期刊上,样本规模与终点设置同西方试验惯例存在差异,国际同行对其临床证据的强度看法不一。

Related pages on this site

Semax Peptide Structure and Origin

The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.

Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.

Semax Background And Mechanism

Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It was derived from the ACTH(4-10) fragment, a short segment of adrenocorticotropic hormone that lacks the hormonal activity associated with the full-length peptide. Researchers at the Institute of Molecular Genetics in Moscow developed the compound during the 1980s. It has been registered as a pharmaceutical product in Russia and several neighbouring countries, where it is supplied as a nasal solution, and it is also sold internationally as a research chemical.

The proposed mechanism centres on neurotrophic signalling rather than direct receptor activation. Semax is reported to increase expression of brain-derived neurotrophic factor and nerve growth factor in several brain regions, and to shift the balance between excitatory and inhibitory neurotransmitter systems. Interaction with melanocortin receptors has been suggested because of the parent ACTH fragment. Many of these findings come from rodent studies, and the extent to which they translate to human physiology remains an open question.

Background and Development

Russian regulatory authorities approved the peptide for nasal administration, and it remains listed in the national pharmacopoeia under several trade names. Documented indications include acute ischemic stroke, transient ischemic attacks, traumatic brain injury, and certain ophthalmological and neurological conditions. Physicians also prescribe it for cognitive complaints in older patients, although the evidence base for that use is thinner. Outside Russia and a few neighboring states, the substance is not an approved medicine and is sold instead as a research chemical.

Later generations of the molecule include an N-acetylated form and an amidated form, both marketed online alongside the parent peptide. These variants differ in terminal chemistry and stability, and they are frequently discussed in the same breath even though they have not been compared in controlled trials. Supply outside formal healthcare systems comes largely from laboratories that synthesize peptides to order. Purity and identity of these materials vary widely, and no single body oversees the international trade.

Semax is a synthetic heptapeptide developed in the Soviet Union during the 1980s by researchers at the Institute of Molecular Genetics in Moscow. It was designed as a truncated analog of adrenocorticotropic hormone, retaining only the fragment spanning residues four through ten. Investigators sought a peptide that would preserve the cognitive effects associated with ACTH while eliminating the hormonal stimulation of the adrenal cortex. The compound entered clinical use in Russia during the following decade.

Reference notes

The likeness of the spectra of these three gases with those of argon, krypton, and xenon, and their observed chemical inertia led Sir William Ramsay to suggest in 1904 that the "emanations" might contain a new element of the noble-gas family. In 1909, Ramsay and Robert Whytlaw-Gray isolated radon and determined its melting temperature and critical point. Because it does not conform to expected periodic trends, their obtained melting point (the only experimental value) was questioned in 1925 by Friedrich Paneth and E. Rabinowitsch, but ab initio Monte Carlo simulations from 2018 agree almost exactly with Ramsay and Gray's result. In 1910, they determined its density (that showed it was the heaviest known gas) and its position in the periodic table. They wrote that "L'expression l'émanation du radium est fort incommode" ("the expression 'radium emanation' is very awkward") and suggested the new name niton (Nt) (from Latin: nitens, shining) to emphasize the radioluminescence property, and in 1912 it was accepted by the International Commission for Atomic Weights. In 1923, the International Committee for Chemical Elements and International Union of Pure and Applied Chemistry (IUPAC) chose the name of the most stable isotope, radon, as the name of the element. The isotopes thoron and actinon were later renamed 220Rn and 219Rn. This has caused some confusion in the literature regarding the element's discovery as while Dorn had discovered radon the isotope, he was not the first to discover radon the element.

=== Fabrication of pure biomass based membrane === A biomass-based membrane is a membrane made from organic materials such as plant fibers. These membranes are often used in water filtration and wastewater treatment applications. The fabrication of a pure biomass-based membrane is a complex process that involves a number of steps. The first step is to create a slurry of the organic materials. This slurry is then cast onto a substrate, such as a glass or metal plate. The cast is then dried, and the resulting membrane is then subjected to a number of treatments, such as chemical or heat treatments, to improve its properties. One of the challenges in the fabrication of biomass-based membranes is to create a membrane with the desired properties.

The recommended daily allowance (RDA) of methionine (combined with cysteine) for adults is set at 13–14 mg kg-1 day-1 (13–14 mg per kg of body weight per day), but some researchers have argued that this figure is too low, and should more appropriately be 25 mg kg-1 day-1. Despite the importance of sulfur, restrictions of dietary sulfur are sometimes recommended for certain diseases and for other reasons.

=== Affinity chromatography === Affinity chromatography is a method of separating biochemical mixtures, based on a highly specific biologic interaction such as that between antigen and antibody, enzyme and substrate, or receptor and ligand. The method was subsequently adopted for a variety of other techniques. Specific uses of affinity chromatography include antibody affinity, Immobilized metal ion affinity chromatography and purification of recombinant proteins - possibly the most common use of the method. To purify, proteins are tagged e.g. using His-tags or GST (glutathione-S-transferase) tags, which can be recognized by a metal ion ligand, such as imidazole. In 1971, Wilchek and colleagues applied this method to show that protein kinase is composed of regulatory and catalytic subunits. In 1972, Wilchek showed that the method can be used to remove toxic compounds from blood, as exemplified by the removal of heme peptides from blood using immobilized human serum albumin, thus laying the grounds for modern hemoperfusion

Sources: en.wikipedia.org

Notes from published material

Alimentary Pharmacology & Therapeutics is a bimonthly peer-reviewed medical journal concerned with the effects of drugs on the human gastrointestinal and hepato-biliary systems, particularly with relevance to clinical practice. The journal publishes original papers concerned with all aspects of basic and clinical pharmacology, pharmacokinetics, and the therapeutic use of drugs in the alimentary tract including the liver, gall bladder, and pancreas. Its editors are J. M. Rhodes and C. W. Howden.

== Function == DHX8 is localized in the cellular nucleus and stimulated upon RNA presence. This protein is a component of the spliceosome, so it takes part in pre-mRNA splicing. Splicing is the process of joining exons from primary transcripts of messenger RNA and the elimination of intron sequences, by means of a spliceosomal mechanism, so that the mRNA produced is the one without introns, consisting exclusively of the joined exons. Splicing finishes with the spliceosomal complex disassembly and the ATP-dependent liberation of the resulting mature RNAs to the outer of the nucleus. Spliceosome requires conformational changes to be able to catalyze splicing reactions and the later mature mRNA releasing to the outer of the nucleus. One of the ATP-dependent helicase needed for these conformational changes is DHX8. Furthermore, DHX8 plays a key role in the releasing, facilitating the nuclear export of spliced mRNA. Protein characterization has shown that DHX8 has a binding preference for adenine-rich RNA. This binding is followed by ATP hydrolysis and thus, ADP release.

== Public image == Kennedy is known for his pronounced Southern drawl and folksy manner of speaking. He is also known for making quips during speeches and senate hearings. However, some colleagues who knew Kennedy during his Louisiana politics days say that his speaking style is just a persona. Columnist Ed Felien wrote that Kennedy "has all the charm of a Southern gentleman and the venom of a rattlesnake." Politico named Kennedy one of the "biggest social media stars in Congress", alongside Representative Alexandria Ocasio-Cortez, Senator Bernie Sanders, Senator Rand Paul and Representative Brandon Gill.

== Hong Kong usage == On 28 June 1997, Andrew Wong, President of the last Legislative Council of Hong Kong as a British crown colony, which was to be dissolved by the incoming sovereign power over Hong Kong, the People's Republic of China, and replaced by a provisional legislature, declared at the end of its last session: "In accordance with the Standing Orders of the Legislative Council, I now adjourn the Council, sine die."

Coleoids, a shell-less subclass of cephalopods (squid, cuttlefish, and octopuses), have complex pigment containing cells called chromatophores which are capable of producing rapidly changing color patterns. These cells store pigment within an elastic sac which produces the color seen from these cells. Coleoids can change the shape of this sac, called the cytoelastic sacculus, which then causes changes in the translucency and opacity of the cell. By rapidly changing multiple chromatophores of different colors, cephalopods are able to change the color of their skin at astonishing speeds, an adaptation that is especially notable in an organism that sees in black and white. Chromatophores are known to only contain three pigments, red, yellow, and brown, which cannot create the full color spectrum. However, cephalopods also have cells called iridophores, thin, layered protein cells that reflect light in ways that can produce colors chromatophores cannot. The mechanism of iridophore control is unknown, but chromatophores are under the control of neural pathways, allowing the cephalopod to coordinate elaborate displays. Together, chromatophores and iridophores are able to produce a large range of colors and pattern displays.

Sources: en.wikipedia.org

Frequently asked questions

What is Semax chemically?

It is a synthetic peptide of seven amino acids. Its backbone corresponds to a fragment of adrenocorticotropic hormone extended at the carboxyl end. The material is distributed as a lyophilized solid for laboratory use.

Why was the Pro-Gly-Pro tail added?

The extension was introduced to slow enzymatic breakdown of the peptide in biological systems. Natural ACTH fragments are degraded rapidly by peptidases. Adding the tripeptide was intended to extend the window during which the molecule remains intact.

How strong is the clinical evidence?

Most published work consists of animal experiments conducted in a small number of laboratories. Human data are limited in number and size. Whether the observed effects translate into reliable clinical benefit is still unresolved.

In which form is semax typically supplied?

Registered medical products are most often 0.1% nasal drops. Research suppliers ship lyophilized powder, usually in milligram quantities, which is dissolved before use. The active peptide is the same in both cases; presentation and excipients differ.

Network